Stock Traders Purchase Large Volume of Edwards Lifesciences Call Options (NYSE:EW)

Edwards Lifesciences Corporation (NYSE:EW) was the recipient of some unusual options trading on Monday. Stock traders bought 2,518 call options on the company. This represents an increase of 93% compared to the typical daily volume of 1,303 call options.

Insider Buying and Selling

In related news, VP Annette Brüls sold 2,644 shares of the stock in a transaction that occurred on Friday, August 28th. The stock was sold at an average price of $89.98, for a total value of $237,907.12. Following the completion of the transaction, the vice president directly owned 17,984 shares in the company, valued at approximately $1,618,200.32. This represents a 12.82% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, VP Daniel Lippis sold 619 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $92.03, for a total value of $56,966.57. Following the transaction, the vice president owned 40,034 shares of the company’s stock, valued at approximately $3,684,329.02. This represents a 1.52% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 5,664 shares of company stock worth $511,918. Company insiders own 0.31% of the company’s stock.

Institutional Investors Weigh In On Edwards Lifesciences

Several hedge funds and other institutional investors have recently bought and sold shares of EW. Pin Oak Investment Advisors Inc. acquired a new position in Edwards Lifesciences in the second quarter valued at $26,000. TrinityBridge Ltd acquired a new stake in shares of Edwards Lifesciences during the second quarter worth about $27,000. MV Capital Management Inc. acquired a new stake in shares of Edwards Lifesciences during the fourth quarter worth about $26,000. Hanson & Doremus Investment Management purchased a new stake in shares of Edwards Lifesciences in the 1st quarter valued at about $25,000. Finally, Kemnay Advisory Services Inc. purchased a new stake in shares of Edwards Lifesciences in the 4th quarter valued at about $27,000. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Edwards Lifesciences Stock Up 1.6%

EW stock traded up $1.35 during trading on Monday, hitting $85.72. 714,015 shares of the company’s stock were exchanged, compared to its average volume of 4,583,936. The business has a 50-day moving average price of $89.16 and a two-hundred day moving average price of $85.81. The company has a current ratio of 4.52, a quick ratio of 3.77 and a debt-to-equity ratio of 0.06. The stock has a market capitalization of $49.36 billion, a price-to-earnings ratio of 49.25, a PEG ratio of 2.21 and a beta of 0.85. Edwards Lifesciences has a 52-week low of $72.30 and a 52-week high of $96.29.

Edwards Lifesciences (NYSE:EW) last announced its quarterly earnings results on Thursday, July 23rd. The medical research company reported $0.78 EPS for the quarter, beating the consensus estimate of $0.74 by $0.04. Edwards Lifesciences had a net margin of 15.43% and a return on equity of 15.68%. The company had revenue of $1.74 billion for the quarter, compared to analyst estimates of $1.70 billion. During the same period in the prior year, the firm posted $0.67 earnings per share. The firm’s revenue was up 13.6% on a year-over-year basis. Edwards Lifesciences has set its Q3 2026 guidance at 0.710-0.770 EPS and its FY 2026 guidance at 2.950-3.050 EPS. As a group, equities research analysts expect that Edwards Lifesciences will post 3 EPS for the current year.

Analysts Set New Price Targets

A number of brokerages have weighed in on EW. Truist Financial lifted their price target on shares of Edwards Lifesciences from $90.00 to $95.00 and gave the company a “hold” rating in a research report on Thursday, July 16th. Evercore reiterated an “outperform” rating and issued a $100.00 price objective on shares of Edwards Lifesciences in a report on Monday, July 6th. Wall Street Zen raised shares of Edwards Lifesciences from a “hold” rating to a “buy” rating in a research report on Saturday. Royal Bank Of Canada lifted their price objective on Edwards Lifesciences from $100.00 to $110.00 and gave the company an “outperform” rating in a research note on Monday, July 13th. Finally, Citigroup boosted their price target on shares of Edwards Lifesciences from $101.00 to $110.00 and gave the stock a “buy” rating in a report on Wednesday, July 8th. Seventeen analysts have rated the stock with a Buy rating and six have issued a Hold rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus target price of $100.27.

About Edwards Lifesciences

Edwards Lifesciences Corporation (NYSE:EW) is a medical technology company focused on therapies for structural heart disease. Its products are designed to treat conditions affecting the heart valves and related cardiovascular structures, helping patients with diseases such as aortic stenosis, mitral regurgitation and tricuspid valve disorders.

The company’s portfolio includes transcatheter aortic valve replacement systems, including its SAPIEN platform, as well as transcatheter mitral and tricuspid therapies and surgical heart valve products.